A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause

NCT06513104 | Completed Phase 1

• 3 other identifiers: NN9541-4922U1111-1294-34332023-507973-16
• Study Type: interventional
• Target: 47
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to investigate if NNC0519-0130 affects the blood levels of a birth control pill that contains the two hormones ethinylestradiol and levonorgestrel. The study will also look into if NNC0519-0130 affects how fast stomach is emptied. Participants will get the new study medicine NNC0519-0130 and will also get birth control pills and paracetamol. The study will last for about 35 weeks.

Conditions

Diabetes Mellitus, Type 2

Outcome Measures

Primary Outcomes (4)

• Area under the ethinylestradiol plasma concentration time curve during a dosing interval at steady state

  Measured in hours picograms per milliliter (h\*pg/mL).

  Day 8

• Area under the ethinylestradiol plasma concentration time curve during a dosing interval at steady state

  Measured in h\*pg/mL.

  Day 188

• Area under the levonorgestrel plasma concentration time curve during a dosing interval at steady state

  Measured in h\*pg/mL.

  Day 8

• Area under the levonorgestrel plasma concentration time curveduring a dosing interval at steady state

  Measured in h\*pg/mL.

  Day 188

Secondary Outcomes (5)

• Maximum ethinylestradiol plasma concentration at steady state

  Day 8 and Day 188

• Maximum levonorgestrel plasma concentration at steady state

  Day 8 and Day 188

• Area under the paracetamol concentration-time curve for 0-300 minutes following a standardised meal

  Day 1 and Day 181

• Area under the paracetamol concentration-time curve for 0-60 minutes following a standardised meal

  Day 1 and Day 181

• Maximum paracetamol plasma concentration following a standardised meal

  Day 1 and Day 181

Study Arms (1)

NNC0519-0130 + OC+ paracetamol

EXPERIMENTAL

All participants will initiate treatment with paracetamol (once) and oral contraceptive (Levonorgestrel + Ethinylestradiol) treatment only followed by a period with NNC0519-0130 treatment only, thereafter a period with NNC0519-0130, paracetamol (once) and oral contraceptive treatment.

Drug: NNC0519-0130; Drug: Levonorgestrel + Ethinylestradiol; Drug: Paracetamol

Interventions

NNC0519-0130 DRUG

NNC0519-0130 will be administered subcutaneously.

NNC0519-0130 + OC+ paracetamol

Levonorgestrel + Ethinylestradiol DRUG

Levonorgestrel + Ethinylestradiol will be administered orally.

NNC0519-0130 + OC+ paracetamol

Paracetamol DRUG

Paracetamol will be administered orally.

NNC0519-0130 + OC+ paracetamol

Eligibility Criteria

• Age: Up to 45 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Postmenopausal female.
• Age greater than or equal to (≥)45 years at the time of signing informed consent.
• Body weight ≥ 60 kilogram (kg).
• Body mass index (BMI) between 27.0 and 39.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
• Considered to be otherwise healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

You may not qualify if:

• Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol.
• Glycated haemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimoles per mole (mmol/mol)) at screening.
• Any contraindications for the use of the oral contraception used in the study according to the Microgynon Summary of Product Characteristics, including:
• Presence or risk of venous thromboembolism or arterial thromboembolism, e.g., history of migraine with focal neurological symptoms or transitory ischemic attacks.
• Undiagnosed vaginal bleeding.
• Presence or history of breast cancer.
• Presence or history of liver tumours (benign or malignant).
• Positive family history of arterial thromboembolism and/or venous thromboembolism (ever in a sibling or parent especially at relatively early age e.g. below 50).
• Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and anti-phospholipid antibodies (anticardiolipinantibodies, lupus anticoagulant).
• Known hereditary or acquired predisposition to venous thromboembolism, such as Activated Protein C (APC) resistance (including factor V Leiden), antithrombin III deficiency, protein C deficiency or protein S deficiency.
• Dyslipoproteinaemia.
• Use of prescription medicinal products or non-prescription drugs including any herbal medicine known to interfere with the metabolic cytochrome P450 (CYP) pathways, such as hypericum (St. John's Wort), ginseng, garlic, milk thistle, and echinaceae, within 14 days before screening. Exceptions are routine vitamins, occasional use of paracetamol, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation.
• Use of hormone replacement therapy within 4 weeks before screening or intention to initiate treatment with hormone replacement therapy during the study.
• Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Parexel International GmbH

Berlin, 14050, Germany

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Levonorgestrel; Ethinyl Estradiol; Acetaminophen

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Norgestrel; Norpregnenes; Norpregnanes; Norsteroids; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Norpregnatrienes; Estrogenic Steroids, Alkylated; Estradiol Congeners; Gonadal Steroid Hormones; Gonadal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Acetanilides; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Study Officials

• Clinical Transparency (dept. 2834)

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 16, 2024
• First Posted: July 22, 2024
• Study Start: July 18, 2024
• Primary Completion: September 10, 2025
• Study Completion: September 30, 2025
• Last Updated: March 12, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share

Locations

DE (1)